Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

COVID-19

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Novel all-in-one vaccine developed to tackle future coronavirus threats

COVID-19

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Professor Sir Andrew Pollard Awarded the James Spence Medal in 2022

Awards & Appointments

Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

COVID-19

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

Oral paratyphoid vaccine to begin human trials

The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.

Oxford to work with Brazil to establish clinical research hub

COVID-19 Research

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

Professor Sue Ann Costa Clemens awarded an Honorary CBE

Awards & Appointments

Congratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.

We shouldn’t be giving Covid boosters while millions wait for a first dose

There’s no evidence yet that top-up shots are needed, so let’s help those around the world who urgently need the vaccine - writes Andrew Pollard in an opinion piece for The Guardian.

University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships

Awards & Appointments

Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.

One billion doses: A moment to celebrate but not a time to be complacent

COVID-19

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.

Severe disease, not mild infection, makes a pandemic – vaccines still offer our best hope

COVID-19

If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.

Oxford vaccine reaches one billion doses released

COVID-19

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Research

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Awards & Appointments COVID-19

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

Publication

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

COVID-19

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

COVID-19 Research

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

COVID-19

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.

Load More